Trevena (TRVN) Stock Price

Trevena Price

NASDAQ·CLOSED
0.00
​
Market closed

Over the last 12 years Trevena grew revenue by 2.1% annually, reaching 3.13 M USD. For Trevena, the net margin of -1,289.2% is up versus -80,229.0% a few years ago.

Trevena stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trevena business model & stock analysis

Trevena, Inc. develops and commercializes novel medicines for central nervous system disorders, focusing on OLINVO for moderate-to-severe acute pain management in hospitals and ambulatory surgery centers. The company commercializes OLINVO in the United States under its own brand, targeting healthcare providers in acute care settings. TRV250, a non-narcotic migraine treatment with potential for other CNS indications, is in Phase I development in the United Kingdom, with the company advancing its research through its ABLE product platform. Trevena leverages its ABLE platform to identify GPCR-targeted biased ligands, supporting its pipeline development without external partnerships or third-party sales. The company generates revenue through the commercialization of OLINVO in the U.S. acute care market, with healthcare facilities and providers as primary buyers. TRV250 remains in development, with no current sales, but the company anticipates future revenue once it progresses through clinical trials. Trevena’s ABLE platform serves as a foundational asset for discovering new compounds, reducing reliance on external licensing or collaborations. Its focus on G protein pathway selective modulators and biased ligands differentiates its product portfolio in CNS therapeutics.

Frequently asked questions about Trevena

6 analysts currently rate the Trevena stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Trevena to generate revenue of 3.00 M USD and earnings per share of -0.31 USD.

Converted at the current exchange rate, the Trevena share trades at 0.00 EUR (0.00 USD).

The Trevena share (TRVN) is listed on 5 stock exchanges, including: NASDAQ (TRVN), SIX (Zürich) (6T4.SW), Frankfurt (6T4.F), München (6T4.MU), Düsseldorf (6T4.DU).

The expected revenue of Trevena is 3.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Trevena is -213,948.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Trevena is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Trevena stock.

The price-to-sales ratio (P/S) of Trevena is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Trevena stock.

The Eulerpool Quality Score for Trevena is 5/10.

The ISIN of Trevena is US89532E3071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Trevena is A1XDSL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Trevena is TRVN. The ticker symbol is used to trade Trevena shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
130,208.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website trevena.com
Currency
USD
Initial public offering
Jan 31, 2014
ISIN
US89532E3071
Cusip
89532E109
Sedol
BGDW0N7
Market capitalization
254.70 USDMicro Cap
52-Week Range
PEG
0.00
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/S
P/Se
—
EV/EBIT
0.84
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-140.93 %
Last updated Nov 20, 2026, 6:24 AM

Trevena Ticker

DÜSSELDORF · 6T4.DUFRANKFURT · 6T4.FMUNICH · 6T4.MUNASDAQ · TRVNSIX · 6T4.SW

All fundamentals and in-depth analysis of Trevena

Our stock analysis for Trevena stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trevena. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.